This investigation, conducted within a multicenter, randomized, double-blind, placebo-controlled trial framework, found that among patients who had experienced acute coronary syndromes and were treated with high-dose statin therapy, treatment with alirocumab, a PCSK9 inhibitor, was associated with a reduced risk of recurrent ischemic cardiovascular events compared to placebo. Here, PCSK9 is linked to acute coronary syndrome.